|
Abuharbeid
S, Apel J, Zugmaier G, Sander M, Gilbert S, Czubayko F, Aigner A.
Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells.
Arch Pharmacol Naunyn-Schmiedeberg 371(2)
(2005) 141-151
Baumann F, Schmidt R, Teichert J, Preiss R
Influence of protein binding on acrolein turnover in vitro by
oxazaphosphorines and liver microsomes.
J Clin Lab Anal 2005; 19(3): 103-109
Grzelinski
M, Bader N, Czubayko F, Aigner A.
Ribozyme-targeting reveals the rate-limiting role of pleiotrophin (PTN)
in glioblastoma
Int J Cancer 117(6)
(2005) 942-951
Regenthal R, Kunstler U, Hesse S, Sabri O,
Preiss R
D2 dopamine receptor occupancy, risperidone plasma level and
extrapyramidal motor symtoms in previously drug-free schizophrenic
patients.
Int J Clin Pharmacol Ther 2005; 43: 370-378
Teichert J, Sohr R,Baumann F, Henning L,
Merkle K, Caca
K, Preiss R
Synthesis and characterization of some new phase II metabolites of the
alkylator bendamustine and their identification in human bile, urine,
and plasma from patients with cholangiocarcinoma.
Drug Metab Dispos 2005; 33(7): 984-992
Teichert J, Tuemmers T, Achenbach H, Preiss
C, Hermann
R, Ruus P, Preiss R
Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney
damage and end-stage renal disease.
J Clin Pharmacol 2005; 45(3): 313-328
Urban-Klein
B, Werth S, Czubayko F, Aigner A.
RNAi-mediated gene-targeting through direct application
of synthetic PEI-complexed siRNA in vitro and in vivo.
Gene Ther 12(5)
(2005) 461-466
Zeng J,
Aigner A, Czubayko F, Greiner A.
Poly(vinyl alcohol) nanofibers by electrospinning as a
protein delivery system and the retardation of enzyme release by
additional polymer coatings.
Biomacromolecules 6(3)
(2005) 1484-8
|